SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001019056-17-000749
Filing Date
2017-11-09
Accepted
2017-11-08 19:00:20
Documents
1
Group Members
DAVID HURWITZJOHN T. BIRDNEIL H. KOFFLERPETER M. COLLERYSC FUND MANAGEMENT PROFIT SHARING PLANSC FUNDAMENTAL LLCSC FUNDAMENTAL VALUE FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A aviragen_13da1.htm SC 13D/A 173732
  Complete submission text file 0001019056-17-000749.txt   175881
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13D/A | Act: 34 | File No.: 005-31596 | Film No.: 171187877
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O SC FUNDAMENTAL LLC 747 THIRD AVENUE, 27TH FLOOR NEW YORK NY 10017
Business Address C/O SC FUNDAMENTAL LLC 747 THIRD AVENUE, 27TH FLOOR NEW YORK NY 10017 212-888-9100
SC Fundamental Value Fund, L.P. (Filed by) CIK: 0001322318 (see all company filings)

IRS No.: 133563962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A